incretin and glp-1 Hormones Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches PDB-101: Molecule of the Month:

The most reported issues are increased nausea, vomiting, indigestion, and acid reflux

"A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity." European Journal of Clinical Pharmacology 80.5 (2024): 669-676

Retatrutide represents a major medical breakthrough

Tirzepatide has the potential benefit of improving metabolic control and cardiovascular function because of its dual activity on GIP and GLP-1 receptors

Retatrutide has produced notable average weight loss in phase 2 research, yet it still needs larger studies, longer follow-up, and regulatory review before any standard dosing approach can be defined for routine care

Other NASH-related biomarkers were decreased, and adiponectin was increased in patients with T2DM [62]